The Patent Finder

Arimoclomol for Treating Glucocerebrosidase Associated Disorders

Zevra Denmark A/S

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US 11,253,505Arimoclomol for Treating Glucocerebrosidase Associated Disorders
In force
 · Medium confidence
Zevra Denmark A/SIn forceMedium confidence
Application 17/574,239Arimoclomol for Treating Glucocerebrosidase Associated Disorders
Abandoned
Abandoned Dec 12, 2025
Zevra Denmark A/SAbandonedAbandoned Dec 12, 2025
Application 19/315,132Arimoclomol for Treating Glucocerebrosidase Associated Disorders
Pending
Not granted
Zevra Denmark A/SPendingNot granted
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
1 of these is in force and held by Zevra Denmark A/S.
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited